Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2001

View Archived Issues

AlphaOne changes name to Arriva

Recombinant AnergiX.RA to be codeveloped by Corixa and Organon

Versicor announces expansion of collaboration with Pharmacia on oxazolidinones

AltaRex reports positive phase II results from OvaRex trials

Alliance completes acquisition of Molecular Biosystems

Bicyclic lactam thrombin inhibitors as promising new i.v. antithrombotic agents

Potential role for betacellulin in endocrine pancreas function and diabetes

New glycopeptide antibiotics with improved profiles

Compounds promoting proteoglycan production claimed by Sumitomo

Chemokine inhibitors described by Teijin for rheumatoid arthritis and other disorders

First evidence that influenza vaccination reduces risk of recurrent MI

TNF-alpha-inhibitory thiazolopyrimidines patented by group at U. of California

Merck scientists disclose new series of imidazole-based cytokine inhibitors

Major advances in infertility treatment announced by Serono

Long-term effects of isobutyramide in beta-thalassemia

NCI compounds targeting tumors in the brain licensed by Ivax

GlaxoSmithKline's Trizivir receives E.U. approval

Pivotal trial of Avicine begins in colorectal cancer

NeoOncoRx to acquire worldwide rights to novel class of anticancer agents

U.K. MCA grants marketing clearance for Periostat tablets

BioMarin's rhASB designated an orphan drug in Europe for MPS-VI

Phase III trial of PolyphenonE commences in Germany and Russia for treatment of genital warts

Antibody research at Lilly to be accelerated using Trans-Phase Technology

Preliminary phase IIa results show potential of ALT-711 to treat isolated systolic hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...